

## Fungicide Efficacy for Control of Corn Foliar Diseases

The **Corn Disease Working Group (CDWG)** developed ratings for how well fungicides control major corn diseases in the United States. The CDWG determined efficacy ratings for each fungicide listed in the table by field testing the materials over multiple years and locations. Ratings are based on the product's level of disease control and does not necessarily reflect yield increases obtained from product application. A product's efficacy depends upon proper application timing, rate, and application method as determined by the product label and overall disease level in the field at the time of application. Differences in efficacy among each fungicide product were determined by directly comparing products in field tests using a single application of the labeled rate. For application timing and use considerations, please contact your local cooperative extension service. The table is not intended to be a list of all labeled products. Additional fungicides are labeled for disease on corn. Other fungicides may be available for diseases not listed in the table, including *Diplodia*, *Gibberella*, and *Fusarium* ear rots. Many products have specific use restrictions about the amount of active ingredient that can be applied within a period of time or the amount of sequential applications that can occur. Read and follow all use restrictions prior to applying any fungicide.



**Southern rust**  
Image: Travis Faske



**Gray leaf spot**  
Image: Adam Sisson

### Find Out More

The **Crop Protection Network (CPN)** is a multi-state and international collaboration of university and provincial extension specialists, and public and private professionals who provide unbiased, research-based information to farmers and agricultural personnel. Our goal is to communicate relevant information that will help professionals identify and manage field crop diseases.

Find more crop disease resources at [CropProtectionNetwork.org](http://CropProtectionNetwork.org)



**We Are Extension**

This article is partially funded by U.S. corn farmers through the National Corn Growers Association. This publication was developed by members of the Corn Disease Working Group. It was compiled and published by Kiersten Wise, University of Kentucky.

The information in this publication is only a guide, and the authors assume no liability for practices implemented based on this information. Reference to products in this publication is not intended to be an endorsement to the exclusion of others that may be similar. Individuals using such products assume responsibility for their use in accordance with current directions of the manufacturer.

In accordance with Federal civil rights law and U.S. Department of Agriculture (USDA) civil rights regulations and policies, the USDA, its Agencies, offices, and employees, and institutions participating in or administering USDA programs are prohibited from discriminating based on race, color, national origin, religion, sex, gender identity (including gender expression), sexual orientation, disability, age, marital status, family/parental status, income derived from a public assistance program, political beliefs, or reprisal or retaliation for prior civil rights activity, in any program or activity conducted or funded by USDA (not all bases apply to all programs). Remedies and complaint filing deadlines vary by program or incident.

Persons with disabilities who require alternative means of communication for program information (e.g., Braille, large print, audiotope, American Sign Language, etc.) should contact the responsible Agency or USDA's TARGET Center at (202) 720-2600 (voice and TTY) or contact USDA through the Federal Relay Service at (800) 877-8339. Additionally, program information may be made available in languages other than English.

To file a program discrimination complaint, complete the USDA Program Discrimination Complaint Form, AD-3027, found online at [How to File a Program Discrimination Complaint](http://How to File a Program Discrimination Complaint) and at any USDA office or write a letter addressed to USDA and provide in the letter all of the information requested in the form. To request a copy of the complaint form, call (866) 632-9992. Submit your completed form or letter to USDA by: (1) mail: U.S. Department of Agriculture, Office of the Assistant Secretary for Civil Rights, 1400 Independence Avenue, SW, Washington, D.C. 20250-9410; (2) fax: (202) 690-7442; or (3) email: [program.intake@usda.gov](mailto:program.intake@usda.gov).

USDA is an equal opportunity provider, employer, and lender.  
©2024 by the Crop Protection Network. All rights reserved.



## Fungicide Efficacy for Control of Corn Foliar Diseases Table (01/2024)

### Efficacy categories:

P = Poor; F = Fair; G = Good; VG = Very Good; E = Excellent; NL = Not labeled for use against this disease; U = Unknown efficacy or insufficient data to rank product.

### Fungicide mode of action groups:

Group 11 QoI Strobilurins      Group 3 DMI Triazoles      Group 7 SDHI

|    | Active ingredient (%)      | Product/Trade name                   | Rate/A (fl oz) | Commonly tested rate/A (fl/oz) | Anthraco-<br>nose<br>leaf blight | Common rust | Eyespot | Gray leaf spot | Northern corn<br>leaf blight | Southern rust | Tar spot <sup>1</sup> | Harvest<br>Restriction <sup>2</sup> |
|----|----------------------------|--------------------------------------|----------------|--------------------------------|----------------------------------|-------------|---------|----------------|------------------------------|---------------|-----------------------|-------------------------------------|
| 11 | Azoxystrobin 22.9%         | Quadris 2.08 SC, multiple generics   | 6.0-15.5       | 6                              | VG                               | E           | VG      | E              | G                            | VG            | NL                    | 7 days                              |
|    | Pyraclostrobin 23.6%       | Headline 2.09 EC/SC                  | 6.0-12.0       | 6                              | VG                               | E           | E       | E              | VG                           | VG            | NL                    | 7 days                              |
| 3  | Picoxystrobin 22.5%        | Aproach 2.08 SC                      | 3.0-12.0       | 6                              | VG                               | VG-E        | VG      | F-VG           | VG                           | G             | G <sup>3</sup>        | 7 days                              |
|    | Flutriafol 20.9%           | Xyway LFR 1.92 SC                    | LFR: 5.8-15.2  | 15.2                           | NL                               | U           | NL      | G              | VG                           | NL            | P <sup>3</sup>        | 7 days                              |
| 3  | Flutriafol 26.4%           | Xyway 3D 2.5 SC                      | 3D: 5.8-11.8   | 11.8                           |                                  |             |         |                |                              |               |                       |                                     |
|    | Propiconazole 41.8%        | Tilt 3.6 EC, multiple generics       | 2.0-4.0        | 4                              | NL                               | VG          | E       | G              | G                            | F             | NL                    | 30 days                             |
| 3  | Prothioconazole 41.0%      | Proline 480 SC                       | 5.7            | 5.7                            | U                                | VG          | E       | U              | VG                           | G             | NL                    | 14 days                             |
|    | Tebuconazole 38.7%         | Folicur 3.6 F, multiple generics     | 4.0-6.0        | NA                             | NL                               | U           | NL      | U              | VG                           | F             | NL                    | 36 days                             |
| 3  | Tetraconazole 20.5%        | Domark 230 ME                        | 4.0-6.0        | NA                             | U                                | U           | U       | E              | VG                           | G             | U                     | R3 (milk)                           |
|    | Azoxystrobin 13.5%         | Quilt Xcel 2.2 SE, multiple generics | 10.5-14.0      | 10.5                           | VG                               | VG-E        | VG-E    | E              | VG                           | VG            | U                     | 30 days                             |
| 7  | Propiconazole 11.7%        | Trivapro 2.21 SE                     | 13.7           | 13.7                           | U                                | U           | U       | E              | VG                           | E             | G-VG                  | 30 days                             |
| 11 | Azoxystrobin 10.5%         |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Propiconazole 11.9%        |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 3  | Cyproconazole 7.17%        | Aproach Prima 2.34 SC                | 3.4-6.8        | 6.8                            | U                                | U           | U       | E              | VG                           | G             | G-VG                  | 30 days                             |
| 11 | Picoxystrobin 17.94%       |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Flutriafol 19.3%           | Fortix 3.22 SC                       | 4.0-6.0        | 5                              | U                                | U           | U       | E              | VG                           | VG            | G-VG <sup>3</sup>     | 30 days                             |
| 11 | Fluoxastrobin 14.84%       | Preemptor 3.22 SC                    |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Flutriafol 26.74%          | Lucento 4.17 SC                      | 3.0-5.5        | 5                              | U                                | U           | U       | VG-E           | VG                           | G-VG          | G                     | 30 days                             |
| 7  | Bixafen 15.55%             |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 3  | Flutriafol 18.63%          | Topguard EQ 4.29 SC                  | 5.0-7.0        | 5                              | U                                | F           | U       | VG             | G-VG                         | G-VG          | G-VG <sup>3</sup>     | 7 days                              |
| 11 | Azoxystrobin 25.30%        |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Mefentrifluconazole 17.56% | Veltyma 3.34 SC                      | 7.0-10.0       | 7                              | U                                | U           | U       | VG-E           | VG-E                         | VG            | VG                    | 21 days                             |
| 11 | Pyraclostrobin 17.56%      |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Mefentrifluconazole 11.61% | Revytek 4.44 SC                      | 8.0-15.0       | 8                              | U                                | U           | U       | VG-E           | VG-E                         | VG            | VG                    | 21 days                             |
| 7  | Fluxapyroxad 7.74%         |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 11 | Pyraclostrobin 15.49%      |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Prothioconazole 16.0%      | Delaro325 SC                         | 8.0-12.0       | 8                              | VG                               | E           | VG      | E              | VG                           | G-VG          | G-VG                  | 14 days                             |
| 11 | Trifloxystrobin 13.7%      |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Prothioconazole 14.9%      | Delaro Complete 3.83 SC              | 4.0-12.0       | 8                              | U                                | U           | U       | E              | VG                           | G-VG          | VG                    | 14 days                             |
| 7  | Fluopyram 10.9%            |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 11 | Trifloxystrobin 13.1%      |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Pydiflumetofen 7.0%        | Miravis Neo 2.5 SE                   | 13.7           | 13.7                           | U                                | U           | U       | E              | VG-E                         | VG            | G-VG                  | 30 days                             |
| 11 | Azoxystrobin 9.3%          |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Propiconazole 11.6%        |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 3  | Pyraclostrobin 28.58%      | Priaxor 4.17 SC                      | 4.0-8.0        | 5                              | U                                | VG          | U       | VG             | VG-E                         | VG            | U                     | 21 days                             |
| 7  | Fluxapyroxad 14.33%        |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 11 | Pyraclostrobin 13.64%      | Headline AMP 1.68 SC                 | 10.0-14.4      | 10                             | U                                | E           | E       | E              | VG                           | G             | G-VG <sup>3</sup>     | 20 days                             |
|    | Metconazole 5.14%          |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 11 | Trifloxystrobin 32.3%      | Stratego YLD 4.18 SC                 | 2.0-5.0        | 4                              | VG                               | E           | VG      | E              | VG                           | G             | NL                    | 14 days                             |
|    | Prothioconazole 10.8%      |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
| 3  | Tetraconazole 7.48%        | Affiance 1.5 SC                      | 10.0-17.0      | NA                             | U                                | G-VG        | U       | G-VG           | G-VG                         | G             | G <sup>3</sup>        | 7 days                              |
| 11 | Azoxystrobin 9.35%         |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Flutriafol 15.7%           | Adastrio 4.0 SC                      | 7.0-9.0        | 8                              | U                                | U           | U       | U              | U                            | VG            | U <sup>3</sup>        | 30 days                             |
| 11 | Azoxystrobin 15.7%         |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |
|    | Fluidapyr 10.5%            |                                      |                |                                |                                  |             |         |                |                              |               |                       |                                     |

Indicates product with mixed fungicide classes

<sup>1</sup>Fungicide application timing is extremely important and needs to be made near the onset of the tar spot symptoms. Efficacy ratings based on limited site locations from 2018 to 2023. <sup>2</sup>Harvest restrictions are listed for field corn harvested for grain. Restrictions may vary for other types of corn (sweet, seed, or popcorn, etc.), and corn for other uses such as forage or fodder. <sup>3</sup>A 2ee label is available for several fungicides for control of tar spot, however efficacy data are limited. Check 2ee labels carefully, as not all products have 2ee labels in all states. This information is provided only as a guide. It is the applicator's legal responsibility to read and follow all current label directions. Reference in this publication to any specific commercial product is for general information only, and does not constitute an endorsement or recommendation by the CDWG. Individuals using such products assume responsibility for their use in accordance with current directions of the manufacturer. Members or participants in the CDWG assume no liability resulting from the use of these products.